New drug combo may help High-Risk kidney cancer patients avoid full kidney removal

NCT ID NCT07389629

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated Apr 25, 2026 · Updated 16 times

Summary

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can shrink kidney tumors enough to allow partial kidney removal in patients who otherwise would need full kidney removal. About 25 adults with localized clear cell renal cell carcinoma and high surgical risk (R.E.N.A.L. score ≥10) will receive the drugs for a few weeks before surgery. The main goal is to see if the tumor complexity score decreases, making surgery safer and preserving more kidney function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, 0755, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CLEAR CELL RENAL CELL CARCINOMA IPAROMLIMAB AND TUVONRALIMAB NEOADJUVANT THERAPY